市場調査レポート

商品コード

1533611

リキッドバイオプシーの市場規模、シェア、成長分析：製品・サービス別、循環バイオマーカー別、技術別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Liquid Biopsy Market Size, Share, Growth Analysis, By Product & Services, By Circulating Biomarker, By Technology, By End User, By Region - Industry Forecast 2024-2031

出版日: 2024年08月05日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のリキッドバイオプシーの市場規模は、2022年に約92億8,000万米ドルとなり、2023年の103億2,000万米ドルから上昇し、予測期間（2024年～2031年）のCAGRは11.21%で、2031年までには241億4,000万米ドルに達すると予測されています。

リキッドバイオプシー市場は、世界のがん罹患率の増加と、より迅速で侵襲性の低い診断方法に対する需要の高まりにより、大きな成長を遂げています。米国では近年、非小細胞肺がんが肺がんの中で最も罹患率の高いタイプとして浮上しています。2010年から2017年の間に米国で報告された非小細胞肺がんの新規症例は約128万件でした。この高い罹患率は、がんを効率的に検出し、的を絞った治療計画の策定に役立つリキッドバイオプシー検査のような高度な診断ツールの必要性を浮き彫りにしています。さらに、リキッドバイオプシー技術の利用が増加していることは、個別化医療や精密腫瘍学への幅広いシフトを反映しています。このような高度な診断法は、病気の進行や治療効果をリアルタイムでモニタリングできるため、従来の組織生検に比べて大きな利点があります。この機能により、よりタイムリーでオーダーメイドの介入が可能となります。ヘルスケアの焦点は引き続き早期発見とカスタマイズされた治療アプローチに置かれているため、リキッドバイオプシー市場は堅調な拡大が見込まれています。この成長は、技術の進歩、調査活動の活発化、ヘルスケア専門家と患者双方の意識の高まりによって促進されます。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主要な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

F. Hoffmann-La Roche Ltd（Switzerland）
Thermo Fisher Scientific Inc.（US）
Illumina, Inc.（US）
Guardant Health, Inc.（US）
Biocept, Inc.（US）
Sysmex Corporation（Japan）
Menarini Silicon Biosystems（Italy）
Natera, Inc.（US）
Biocartis Group NV（Belgium）
Personal Genome Diagnostics Inc.（US）
Exosome Diagnostics, Inc.（US）
Bio-Rad Laboratories, Inc.（US）
OncoCyte Corporation（US）
Adaptive Biotechnologies Corporation（US）
Angle plc（United Kingdom）
Epic Sciences, Inc.（US）
NEOGENOMICS LABORATORIES（US）
CellMax Life（US）
MENARINI-SILICON BIOSYSTEMS（Italy）
LUNGLIFE AI, INC.（US）
VORTEX BIOSCIENCES（US）

Product Code: SQMIG35J2060

Global Liquid Biopsy Market was valued at around 9.28 billion in 2022 and is expected to rise from USD 10.32 billion in 2023 to reach a value of USD 24.14 billion by 2031, at a CAGR of 11.21% during the forecast period (2024-2031).

The liquid biopsy market has experienced significant growth due to the increasing global incidence of cancer and the rising demand for faster, less invasive diagnostic methods. In the United States, non-small-cell lung cancer has emerged as the most prevalent type of lung cancer in recent years. Between 2010 and 2017, there were approximately 1.28 million new cases of non-small-cell lung cancer reported in the US. This high incidence highlights the need for advanced diagnostic tools such as liquid biopsy tests, which can efficiently detect cancer and help develop targeted treatment plans. Moreover, the growing use of liquid biopsy techniques reflects a broader shift towards personalized medicine and precision oncology. These advanced diagnostic methods offer significant advantages over traditional tissue biopsies by enabling real-time monitoring of disease progression and treatment efficacy. This capability allows for more timely and tailored interventions. As the focus of healthcare continues to emphasize early detection and customized treatment approaches, the liquid biopsy market is expected to expand steadily. This growth is fueled by technological advancements, increased research activities, and heightened awareness among both healthcare professionals and patients.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liquid Biopsy Market Segmental Analysis

The liquid biopsy market is segmented by Product & Services, Circulating Biomarker, Clinical Application, Technology, Application, Sample Type, End-User and Region. Based on Product & Services, the market is segmented into Assay Kits, Instruments, and services. Based on Circulating Biomarker, the market is segmented into Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA, Extracellular Vesicles, and Others. Bases on Clinical Applications, the market is segmented into Early Cancer Screening, Therapy Selection, Treatment Monitoring, and Recurrence Monitoring. Based on Technology, the market is segmented into Multi-Gene Parallel Analysis using NGS, and Single-Gene Analysis using PCR. Based on Application, the market is segmented into Cancer Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, and Others), Non-Cancer Application (Non-Invasive Prenatal Testing, Organ Transplantation, and Infectious Disease Testing). Based on Sample Type, the market is segmented into Blood Samples, Urine Sample, Saliva Sample, and Others. Based on End-User the market is segmented into Hospitals & Clinics, Diagnostic Centers, Reference Laboratories, Academic & Research Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Liquid Biopsy Market

Liquid biopsy techniques offer several advantages over traditional biopsies. As previously noted, they are minimally invasive, resulting in less patient discomfort and making them a more acceptable option for those undergoing diagnostic procedures. Additionally, liquid biopsies are highly effective at capturing tumor heterogeneity, providing a comprehensive view of cancer evolution that facilitates personalized treatment strategies. They also enable real-time monitoring, allowing healthcare providers to track disease progression more accurately and implement timely interventions, which can lead to better patient outcomes. Consequently, the advancements in liquid biopsy methods are preferred by both patients and healthcare providers, driving increased demand and adoption in clinical practice.

Restraints in the Global Liquid Biopsy Market

The liquid biopsy market faces several key challenges, including a lack of standardization and regulatory guidelines. The process of obtaining regulatory approval for liquid biopsy tests is often complex and time-consuming, which can delay the introduction of new products to the market. Additionally, the high cost of liquid biopsy tests and limited reimbursement coverage in certain regions may hinder market growth. Addressing these challenges could involve the development of standardized guidelines and improvements in reimbursement coverage for liquid biopsy tests, which would help mitigate these obstacles and support market expansion.

Market Trends of the Global Liquid Biopsy Market

A significant trend in the liquid biopsy market is the growing use of next-generation sequencing (NGS) technology. NGS facilitates high-throughput sequencing of DNA and RNA, enabling the detection of numerous cancer biomarkers from a single sample. This technology is becoming increasingly favored in liquid biopsy tests due to its ability to provide highly sensitive and specific results. These capabilities enhance early cancer detection and allow for effective monitoring of treatment responses. As the demand for NGS-based liquid biopsy tests continues to rise, it is anticipated to drive substantial growth in the market in the years ahead.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Green Chemical Insights

Technology Analysis
Ecosystem of the Market
Value Chain Analysis
Patent Analysis
Case Study Analysis
Trade Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Liquid Biopsy Market by Products & Services

Market Overview
Assay Kits
Instruments
Services

Liquid Biopsy Market by Circulating Biomarkers

Market Overview
Circulating Tumor Cells
Circulating Tumor DNA
Cell free DNA
Extracellular Vesicles
Others

Liquid Biopsy Market by Clinical Application

Market Overview
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring

Liquid Biopsy Market by Technology

Market Overview
Multi-Gene Parallel Analysis using NGS
Single-Gene Analysis using PCR

Liquid Biopsy Market by Application

Market Overview
Cancer Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Others
Non-Cancer Application
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Infectious Disease Testing

Liquid Biopsy Market by Sample Type

Market Overview
Blood Samples
Urine Sample
Saliva Sample
Others

Liquid Biopsy Market by End-User

Market Overview
Hospitals & Clinics
Diagnostic Centers
Reference Laboratories
Academic & Research Centers
Others

Liquid Biopsy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocept, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Menarini Silicon Biosystems (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personal Genome Diagnostics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exosome Diagnostics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OncoCyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Angle plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NEOGENOMICS LABORATORIES (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CellMax Life (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MENARINI-SILICON BIOSYSTEMS (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LUNGLIFE AI, INC. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
VORTEX BIOSCIENCES (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

リキッドバイオプシーの市場規模、シェア、成長分析：製品・サービス別、循環バイオマーカー別、技術別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Liquid Biopsy Market Size, Share, Growth Analysis, By Product & Services, By Circulating Biomarker, By Technology, By End User, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主要なグリーンケミカルの洞察

リキッドバイオプシー市場：製品・サービス別

リキッドバイオプシー市場：循環バイオマーカー別

リキッドバイオプシー市場：臨床応用別

リキッドバイオプシー市場：技術別

リキッドバイオプシー市場：用途別

リキッドバイオプシー市場：サンプルタイプ別

リキッドバイオプシー市場：エンドユーザー別

リキッドバイオプシー市場規模：地域別